About Cytogel Pharma
Cytogel Pharma is a private company based in Darien, Connecticut. It has reported $8,913,779 raised in ten offerings on Form D since May 2010. Its chief executive is C. Maglaris.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Not yet | Dec 23, 2025amended Mar 26, 2026 | $0of $16.0M target | 0 | — | EquityRule 506(b) | Form D/A ↗2 earlier filings |
| Jun 10, 2023 | Jul 28, 2023amended Oct 11, 2024 | $1,763,884of $2.1M target | 18 | $97,994 | Equity, OptionsRule 506(b) | Form D/A ↗1 earlier filing |
| Jun 15, 2022 | Jul 12, 2022 | $50,000of $1.5M target | 1 | $50,000 | DebtRule 506(b) | Form D ↗ |
| Sep 27, 2019 | Sep 30, 2019amended May 21, 2021 | $956,905of $25.0M target | 12 | $79,742 | EquityRule 506(b) | Form D/A ↗3 earlier filings |
| Mar 6, 2019 | Mar 12, 2019 | $100,000of $200K target | 3 | $33,333 | DebtRule 506(b) | Form D ↗ |
| May 31, 2018 | May 31, 2018 | $161,800of $3.0M target | 5 | $32,360 | Debt, Options, Promissory notes are convertible into equity at maturity if not paid.Rule 506(b) | Form D ↗ |
| Jan 6, 2015 | Jan 7, 2015 | $2,691,190of $8.0M target | 10 | $269K | EquityRule 506(b) | Form D ↗ |
| Mar 20, 2014 | Mar 20, 2014 | $240,000of $1.1M target | 2 | $120K | Debt, Options, Debt is convertible into LLC Units if not paid at maturity.Rule 506(b) | Form D ↗ |
| Feb 6, 2013 | Feb 12, 2013amended Jul 12, 2013 | $750,000of $2.0M target | 6 | $125K | Debt, Options, Debt is convertible into LLC Units if not paid at maturity.06 | Form D/A ↗1 earlier filing |
| May 12, 2010 | May 17, 2010 | $2,200,000fully sold | 7 | $314K | Equity, Options06 | Form D ↗ |
| Total, ten offerings | $8,913,779 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Cytogel Pharma's Form D filed Mar 26, 2026.
Earlier filings also listed William Carello (executive officer and director, last listed Jul 2022), Joseph Rucci (executive officer and director, last listed Mar 2019), Alan Dunton (director, last listed Mar 2019), E. Griwold (director, last listed May 2018), E. Girswold (director, last listed Jan 2015), E. Griswold (director, last listed Mar 2014) and Aniello Bianco (director, last listed Mar 2014).
Sources
- SECCytogel Pharma, LLC Form D/A, filed Dec 23, 2025
- SECCytogel Pharma, LLC Form D, filed Dec 23, 2025
- SECCytogel Pharma, LLC Form D, filed Jul 28, 2023
- SECCytogel Pharma, LLC Form D/A, filed Mar 16, 2021
- SECCytogel Pharma, LLC Form D/A, filed Mar 23, 2020
- SECCytogel Pharma, LLC Form D, filed Sep 30, 2019
- SECCytogel Pharma, LLC Form D, filed Feb 12, 2013
- SECCytogel Pharma, LLC filing history
- CompanyContact Us
- CompanyLeadership
- CompanyBoard of Managers